Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases
-
Published:2023-11-14
Issue:1
Volume:7
Page:
-
ISSN:2397-768X
-
Container-title:npj Precision Oncology
-
language:en
-
Short-container-title:npj Precis. Onc.
Author:
In Gino K.ORCID, Ribeiro Jennifer R.ORCID, Yin Jun, Xiu Joanne, Bustos Matias A., Ito Fumito, Chow FrancesORCID, Zada Gabriel, Hwang Lindsay, Salama April K. S., Park Soo J., Moser Justin C., Darabi SouratORCID, Domingo-Musibay EvidioORCID, Ascierto Maria L., Margolin Kim, Lutzky Jose, Gibney Geoffrey T., Atkins Michael B.ORCID, Izar BenjaminORCID, Hoon Dave S. B.ORCID, VanderWalde Ari M.
Abstract
AbstractMelanoma brain metastases (MBM) are clinically challenging to treat and exhibit variable responses to immune checkpoint therapies. Prior research suggests that MBM exhibit poor tumor immune responses and are enriched in oxidative phosphorylation. Here, we report results from a multi-omic analysis of a large, real-world melanoma cohort. MBM exhibited lower interferon-gamma (IFNγ) scores and T cell-inflamed scores compared to primary cutaneous melanoma (PCM) or extracranial metastases (ECM), which was independent of tumor mutational burden. Among MBM, there were fewer computationally inferred immune cell infiltrates, which correlated with lower TNF and IL12B mRNA levels. Ingenuity pathway analysis (IPA) revealed suppression of inflammatory responses and dendritic cell maturation pathways. MBM also demonstrated a higher frequency of pathogenic PTEN mutations and angiogenic signaling. Oxidative phosphorylation (OXPHOS) was enriched in MBM and negatively correlated with NK cell and B cell-associated transcriptomic signatures. Modulating metabolic or angiogenic pathways in MBM may improve responses to immunotherapy in this difficult-to-treat patient subset.
Funder
U.S. Department of Health & Human Services | National Institutes of Health Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference65 articles.
1. Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7–33 (2022). 2. Gutzmer, R. et al. Melanoma brain metastases - Interdisciplinary management recommendations 2020. Cancer Treat. Rev. 89, 102083 (2020). 3. Janavicius, M., Lachej, N., Anglickiene, G., Vincerzevskiene, I. & Brasiuniene, B. Outcomes of treatment for melanoma brain metastases. J. Skin Cancer 2020, 7520924 (2020). 4. Tawbi, H. A. et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N. Engl. J. Med. 379, 722–730 (2018). 5. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
|
|